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Abstract
Background: Alpha-synuclein is a presynaptic protein with a proposed role in neurotransmission and dopamine
homeostasis. Abnormal accumulation of a-synuclein aggregates in dopaminergic neurons of the substantia nigra is
diagnostic of sporadic Parkinson’s disease, and mutations in the protein are linked to early onset forms of the
disease. The folded conformation of the protein varies depending upon its environment and other factors that are
poorly understood. When bound to phospholipid membranes, a-synuclein adopts a helical conformation that
mediates specific interactions with other proteins.
Results: To investigate the role of the helical domain in transport and localization of a-synuclein, eGFP-tagged
constructs were transfected into rat primary hippocampal neurons at 7 DIV. A series of constructs were analyzed in
which each individual exon was deleted, for comparison to previous studies of lipid affinity and a-helix content.
A53T and A30P substitutions, representing Parkinson’s disease-associated variants, were analyzed as well. Single
exon deletions within the lipid-binding N-terminal domain of a-synuclein (exons 2, 3, and 4) partially disrupted its
presynaptic localization at 17-21 DIV, resulting in increased diffuse labeling of axons. Similar results were obtained
for A30P, which exhibits decreased lipid binding, but not A53T. To examine whether differences in presynaptic
enrichment were related to deficiencies in transport velocity, transport was visualized via live cell microscopy.
Tagged a-synuclein migrated at a rate of 1.85 ± 0.09 μm/s, consistent with previous reports, and single exon
deletion mutants migrated at similar rates, as did A30P. Deletion of the entire N-terminal lipid-binding domain
(Δ234GFP) did not significantly alter rates of particle movement, but decreased the number of moving particles.
Only the A53TGFP mutant exhibited a significant decrease in transport velocity as compared to ASGFP.
Conclusions: These results support the hypothesis that presynaptic localization involves a mechanism that requires
helical conformation and lipid binding. Conversely, the rate of axonal transport is not determined by lipid affinity
and is not sufficient to account for differences in presynaptic localization of a-synuclein-eGFP variants.
Background
Alpha-synuclein (a-syn) is a 140-amino acid protein
enriched at presynaptic terminals of the vertebrate cen-
tral nervous system [1], although significant localization
to other subcellular compartments (nucleus[2,3], endo-
plasmic reticulum[4] and other cell types, including var-
ious glia [5,6]) has also been observed. Its physiological
function is not well understood, but it has been impli-
cated in the regulation of activity-dependent plasticity
[7,8], dopamine biosynthesis [9], and membrane
dynamics at the presynaptic terminal [10,11]. The pro-
tein is intrinsically unstructured [12], but adopts an a-
helical secondary structure when bound to phospholipid
membranes [13]; this induced structure mediates speci-
fic interactions with other proteins [14]. An alternative
b-sheet conformation of a-syn is associated with a num-
ber of neurodegenerative disorders, most prominently
Parkinson’s disease (PD). Misfolded a-syn is the main
fibrillar component of Lewy bodies and Lewy neurites
[15,16], intraneuronal inclusions that are typical of this
disorder. Mutations in a-syn are associated with rare
familial forms of Parkinson’s disease. These mutations
include point mutations [17-19] and duplications or tri-
plications of the gene SNCA [20-22], which encodes a-
syn protein.
The basis of a-syn localization to the presynapse is
unclear. Unlike many classical presynaptic proteins, a-
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syn is not an integral membrane protein of synaptic
vesicles [1,23,24], although it may associate transiently
with these structures [25,26]. Furthermore, its localiza-
tion to the synapse in cultured neurons occurs several
days after functional synapses first form, suggesting that
a-syn is not essential for neurotransmitter release [27].
Recent studies have demonstrated that a-syn undergoes
axonal transport via slow component b (SCb), a process
requiring an intact microtubule cytoskeleton and driven
by the motor proteins kinesin and dynein [28,29]. Con-
sistent with this model, we have found conformation-
dependent interactions between helical (lipid-bound) a-
syn and the motor proteins kinesin light chain 1S
(KLC1S) and the heavy chain of cytoplasmic dynein
(DHC1) [14].
In the present study, we sought to determine whether
membrane binding, and the resultant stabilization of
helical protein conformation, is essential for either
transport or localization of a-syn to the presynaptic
terminal, using eGFP-tagged a-syn constructs expressed
in rat hippocampal primary neuronal cultures. A similar
eGFP-tagging strategy has been used successfully in stu-
dies of another small presynaptic protein, synapsin,
which was found to localize normally even in the pre-
sence of the large eGFP tag [30]. We systematically
deleted each coding exon, to facilitate correlation of
transport and localization behavior with our previous
studies [13,31] of lipid affinity and a-helix content. We
also analyzed the PD-associated mutants A53T and
A30P. We found that deletions of single exons within
the lipid-binding N-terminal domain of a-syn (exons 2,
3, and 4) or the PD-association mutation A30P partially
disrupted the localization of a-syn at presynaptic term-
inals, resulting in increased diffuse labeling of axons.
A53T exhibited normal presynaptic enrichment, but its
transport velocity was decreased relative to the other
variants. Finally, we observed that deletion of lipid-bind-
ing exons 2-4 resulted in a decreased number of motile,
axonal a-syn-containing particles without affecting
instantaneous velocity of those particles.
Results
To facilitate analysis of the protein domains required for
targeting of a-syn to presynaptic terminals, we
expressed a fusion construct encoding full-length
human a-syn with a C-terminal eGFP tag (ASGFP). As
observed previously for wild-type a-syn [27], ASGFP
stably localizes to presynaptic terminals of primary hip-
pocampal neurons by approximately 14-21 days in vitro
(DIV). In Fig. 1, punctate a-syn staining is observed
adjacent to MAP2 positive dendrites. The a-syn staining
overlaps with staining for the presynaptic protein synap-
sin I. In contrast, eGFP alone is distributed diffusely
within neuronal processes, and is not concentrated at
synapses.
Having thus established that tagged ASGFP localizes
similarly to untagged a-syn, we next analyzed a series of
deletion constructs corresponding to the natural exons
in the SNCA gene (Fig. 2). Five exons (numbered 2
through 6) form the longest splice variant of a-syn (a-
syn 1-140). Exons 2 through 4 (Fig. 2) encode an amphi-
pathic a-helical domain shown previously to mediate
reversible interactions with lipid [31]. We tested dele-
tions of each of the exons individually (Δ2GFP, Δ3GFP,
etc.), and of the entire lipid-binding domain (Δ234GFP).
We also tested eGFP-tagged constructs corresponding
to two known Parkinson’s disease-associated mutations,
A30PGFP and A53TGFP.
Each construct was transfected into primary hippo-
campal neurons and visualized at 17-21 DIV. ASGFP
was observed to localize at discrete punctae along axo-
nal processes, with minimal signal detected in interven-
ing axonal segments (Fig. 3). These punctae presumably
represent presynaptic boutons, as most were immuno-
positive for synapsin I. In contrast to ASGFP, mutants
with partial deletions of the N-terminal helical domain
(Δ2GFP, Δ3GFP, and Δ4GFP) were localized to axonal
punctae, but also maintained residual diffuse staining
along the axon. To quantitate this effect, we calculated
the ratio of the fluorescence intensity at presynaptic
terminals to the signal along the axon, and compared
the resulting localization index for all the mutants (Fig.
4). We found that the localization index was signifi-
cantly reduced for Δ2GFP, Δ3GFP, and Δ4GFP, and
that the effect was even more pronounced for Δ234GFP.
Δ5GFP and Δ6GFP, each with partial deletions of the
unstructured C-terminus, were indistinguishable in loca-
lization from the wild-type construct. For the PD
mutants, we found that A30PGFP exhibited a significant
attenuation of its localization index, while A53TGFP
was unimpaired in its localization.
We reasoned that a failure to concentrate at presynap-
tic sites could result from deficits in transport to
synapses, impaired retention at synapses, or both. With
respect to the former, active axonal transport of a-syn
has been documented previously (see Discussion). We
measured migration of ASGFP-positive particles along
neuritic processes at 10-14 DIV, prior to establishment
of a stable presynaptic localization. These particles were
observed by time-lapse microscopy to move bidirection-
ally within the same neuritic process (Additional file 1),
at times slowing and appearing to interact with more
stationary particles. In Fig. 5A, images from a time-lapse
series illustrate the behavior of two particles moving in
opposite directions along the same neurite (double and
single arrowheads, respectively).
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For analysis of particle velocity, time-lapse series were ren-
dered as kymographs (see Methods). In these kymograph
plots, velocity is represented by the slope of each line (y
length over x time), and a pause in movement is repre-
sented by a horizontal segment. When the series from Fig.
5A is rendered as a kymograph (Fig. 5B), it is evident that
the ASGFP particles move with different velocities. One
particle (double arrowhead) moves rapidly through the
length of the frame, while another particle (single arrow-
head) is initially stationary, then moves a short distance
and pauses before splitting into two particles, one station-
ary (labeled “s”) and one continuing in the original direc-
tion of movement (labeled “m”) (Fig. 5B).
Other examples of ASGFP behavior are illustrated in
Fig. 6. In Fig. 6A, one particle is clearly seen to bifurcate
into two distinct particles; of these, one continues its
motion down the axon, while the other remains station-
ary throughout the duration of measurement. In Fig. 6B,
three starting particles interact in a complex fashion,
moving bidirectionally, fusing, and then splitting again.
Fig. 6C demonstrates how some particles move bidirec-
tionally in and out of a stationary accumulation of a-
syn, while Fig. 6D represents how some particles are
seen to travel in one direction without stopping during
the period of imaging. Last, in Fig. 6E, a distinct particle
slowly emerges, apparently due to the accumulation of
diffuse ASGFP signal.
Velocities were calculated for migrating particles of
mutant and wild-type ASGFP. Only objects with contin-
uous net movements of at least 10 μm were analyzed
and only during periods of motion. In each case a broad
distribution of velocities was measured (Fig. 7 and Table
1). When these data were compared by pairwise t-test, a
slight decrement in mean particle velocity was measured
only for A53T.
However, we measured fewer moving particles overall
for the Δ234GFP variant (Fig. 8). Primary hippocampal
neurons were transfected with ASGFP, Δ234GFP, or
eGFP as a control, and the number of moving particles
in the proximal axon segment of each cell was normal-
ized to its length. Cells transfected with ASGFP con-
tained approximately twice the number of motile
particles as cells transfected with Δ234GFP, which were
comparable to background (eGFP alone). These results
suggest that the N-terminal domain of a-syn may med-
iate its association with transport particles.
Discussion
Intracellular inclusions of a-syn are characteristic of a
variety of neurodegenerative disorders, collectively
termed “synucleinopathies”, of which Parkinson’s disease
is most prominent [32]. In PD, a-syn inclusions can be
either perinuclear (Lewy bodies) or axonal (Lewy neur-
ites). In healthy brain, the distribution of a-syn is
Figure 1 ASGFP localizes to the presynaptic terminal by 17DIV. Primary rat E18 hippocampal neurons were transfected with either ASGFP
(top and middle rows, green) or eGFP (bottom row, green). After 17 days in vitro (DIV), cells were fixed and immunostained for MAP2 (top row,
red), or synapsin I (middle and bottom rows, red), and visualized for immunofluorescence. Scale bar = 10 μm.
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primarily presynaptic, although nuclear localization has
also been noted. In primary hippocampal neurons, a-
syn protein is initially expressed in the cell soma, and
becomes progressively enriched at presynaptic terminals
over several weeks. PD thus involves a mislocalization of
a-syn, and may reflect a failure of the normal processes
of axonal transport and localization of the protein.
In this study, axonal transport and presynaptic locali-
zation of a-syn were dissected via systematic deletion of
each of the 5 coding exons of a-syn. Prior studies in
our laboratory have shown that exons 2, 3, and 4, which
span residues 1-41, 42-56, and 57-102, respectively,
adopt an a-helical conformation in the presence of
lipid, and contribute to cooperative interactions with
phospholipid membranes [31]. Exons 5 and 6 encode a
domain without defined secondary structure, and do not
contribute to membrane binding [33]. Here we show
that eGFP-tagged mutants of a-syn, each lacking one of
the first three coding exons (Δ2GFP, Δ3GFP, and
Δ4GFP), do localize to presynaptic terminals, but with a
lower degree of presynaptic versus axonal enrichment
when compared to the full-length a-syn construct
(ASGFP). A construct in which all three lipid-binding
exons were deleted (Δ234GFP) showed much greater
impairment, while C-terminal mutants (Δ5GFP and
Δ6GFP) were indistinguishable from full-length ASGFP.
/////////////////////
////////
////////////////////////
///////////////////////////////////////////////////////
///////////////
/////
Figure 2 Schematic representation of a-synuclein/eGFP constructs. (A) Schematic of wild-type a-syn with C-terminal eGFP fusion; coding
exons are depicted as blue boxes numbered 2 to 6. Positions of two PD-associated mutations (A30 and A53) are indicated, and black lines
represent the predicted secondary structure in the presence of lipid. (B) Exon deletion mutants; crosshatched boxes represent deleted regions.
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Figure 3 Localization pattern of exon-deletion mutants. Primary rat E18 hippocampal neurons were transfected with a-syn variant
constructs. After 17 DIV, cells were fixed and immunostained for synapsin I. The left column shows the eGFP signal from the various a-syn
constructs (green). The middle employs the “find edges” filter in Adobe Photoshop, which represents color transitions as lines. The right column
shows a merge of the eGFP signal from the various a-syn constructs (green) with the synapsin I staining (red).
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These results demonstrate a positive correlation between
membrane binding and presynaptic enrichment of a-syn
deletion mutants.
We also measured the presynaptic enrichment of the
PD mutants A53TGFP and A30PGFP. Prior studies have
indicated that A53T binds membranes with similar or
even greater affinity than wild-type a-syn [31]. In con-
trast, A30P has a proline residue in exon 2, which tends
to disrupt the N-terminal lipid-binding a-helix [34],
decreasing its affinity for lipid membranes [31]. We
found that A53T was enriched at presynaptic terminals
of primary hippocampal neurons, while A30P was much
less enriched, relative to wild-type ASGFP. This too is
consistent with a role for lipid-binding in normal presy-
naptic localization.
Using viral expression of a-syn GFP constructs,
Specht et al. have previously reported that presynaptic
localization of a-syn depends on an intact N-terminus
[35]. In contrast to our results, they found that deletion
of residues 1-19 was sufficient to completely inhibit a-
syn localization to the presynapse, while we found that
an even more extensive deletion (Δ2GFP, lacking resi-
dues 1-41) only partially inhibited localization. The time
courses of our respective experiments were quite differ-
ent: they measured localization of a-syn after just 5
hours of viral infection, while we made our measure-
ments after ~3-7 days of transfection. It is possible that
the Specht et al. results reflect differences in initial
transport to the presynapse that are not obvious after
longer periods of equilibration. Indeed, Saha et al. [36]
observed decreased transport velocity of A53T and
A30P a-syn after 3-4 hours of transfection that were
not measurable at 5-6 hours.
The use of an exon-based deletion strategy yields
potential insight into the function of natural splice var-
iants of a-syn. For example, the splice variant SNCA
126, which lacks exon 3 (similar to Δ3GFP), is expressed
at relatively lower levels in the frontal cortex of demen-
ted patients [37]. Given our observation that Δ3GFP is
localized less efficiently to presynaptic terminals than
the full-length isoform, we speculate that a difference in
protein localization may underlie the association
between SNCA 126 expression and dementia.
Our conclusion that membrane binding is required for
presynaptic localization is consistent with the observa-
tions of Fortin et al., who report that drugs known to
alter cholesterol and sphingolipid synthesis also disrupt
the presynaptic localization of a-syn [38]. Additional
studies by the same investigators indicate that presynap-
tic localization requires membrane microdomains
enriched for phosphatidylserine headgroups and specific
polyunsaturated side chains [39]. They also note a speci-
fic decrease in lipid affinity and presynaptic localization
by N-terminally eGFP-tagged A30P [26,38]. Taken
together, the available evidence suggests that the selec-
tive concentration of a-syn at presynaptic terminals is
dependent, at least in part, on its affinity for presynaptic
membranes. This affinity is sensitive to perturbations of
the N-terminal helical domain of a-syn (Δ2GFP,
Δ3GFP, Δ4GFP, A30PGFP), and depends on the
Figure 4 Quantification of localization. Bar graph showing the localization index of each construct expressed in neurons. The localization
index is a ratio of average signal intensity from boutons versus average signal intensity from axonal processes. The mean localization index of
each mutant (n = 15 cells) was compared to ASGFP using pairwise t-test with Bonferroni correction for repeated measures (*p < 0.0001, **p =
0.0002).
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presence of specific lipid microdomains within the pre-
synaptic terminal.
Another factor potentially influencing the presynaptic
localization of a-syn is its trafficking along the axon.
Numerous prior studies indicate that a-syn is carried
via slow axonal transport, particularly in slow compo-
nent b (SCb) [28,29,40-42]. Initial experiments measured
bulk transport of labeled a-syn over hours to days,
reflecting net movement of the population of a-syn
molecules in vivo. Jensen et al. [40] measured transport
of 35S-methionine labeled a-syn in the rat visual system,
and concluded that the bulk of a-syn was transported in
SCb. Similarly, Li et al. [41] measured transport of a-
syn in peripheral nerves of A53T and A30P transgenic
mice, and reported that all forms of a-syn (mutant and
wild-type) were transported in the slow component.
Subsequent studies extended these results to cell culture
models, allowing for more acute visualization of the
transport process. Utton et al. [28] performed time-lapse
imaging of a-syn-eGFP in cortical neurons, and mea-
sured behavior consistent with SCb: periods of fast
transport (average velocity 161 mm/day, or 1.86 μm/s)
Figure 5 ASGFP transport behavior. (A) Time lapse fluorescent images of ASGFP transport particles in rat primary hippocampal neurons
visualized at 10 DIV. The single-headed arrow indicates an ASGFP structure that moves along the axon, while the double-headed arrow indicates
an ASGFP structure moving in the opposite direction. (B) Kymograph of the full time lapse series, with the time window depicted in A noted on
top (46-81s). The particles are labeled as in panel A. One of the particles (double-headed arrow) is seen to move continuously in one direction,
while other particle (single-headed arrow) moves in the opposite direction, pauses, and then bifurcates into stationary (s) and motile (m)
particles.
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interspersed with pauses, and frequent changes in the
direction of movement.
We observe similar behavior for eGFP-tagged wild-
type a-syn (ASGFP) in primary rat hippocampal neu-
rons analyzed at 10-14 DIV. In our experiments, ASGFP
exhibited a mean velocity during periods of movement
of ~1.85 μm/s, or 155 mm/day. This rate, if sustained,
would be consistent with fast axonal transport. Only
rarely, however, did ASGFP transport particles move
continuously during the period of observation; most
particles exhibited bidirectional movement punctuated
by frequent pauses. Such behavior is typical of SCb
cargoes, which have been shown to utilize the fast trans-
port machinery yet achieve a lower net transport velo-
city as a consequence of a decreased duty ratio [43].
We applied the exon deletion strategy to assess the
structural requirements for axonal transport of a-syn.
None of the individual exon deletions altered the mean
transport velocity during periods of movement, nor did
the more extensive deletion Δ234GFP. Likewise, trans-
port of A30PGFP was statistically identical to ASGFP.
Only A53TGFP showed a slight decrement in mean
transport velocity. These results indicate that the
decreased presynaptic localization observed for Δ2GFP,
Δ3GFP, Δ4GFP, Δ234GFP, and A30PGFP is not simply
attributable to a failure of axonal transport, and suggest
that differences in localization may be mediated by a
specific lipid-dependent mechanism for retention of
alpha-synuclein at the presynaptic terminal, consistent
with previous reports[26,38]. However, we were unable
to distinguish anterograde and retrograde transport in
our assays, so we cannot exclude the possibility that the
variants we tested might have specific effects on these
different components that are lost when the data are
aggregated.
However, association with the transport machinery
seems to partially depend upon the N-terminus, as com-
plete deletion of this domain (Δ234GFP) resulted in a
decrease in the number of transport particles per unit
axon length, similar to eGFP alone. This implies that
the formation of transport particles may depend upon
the helical N-terminus, while the migration rate of
formed particles does not. Consistent with a role for the
Figure 6 Examples of ASGFP transport behavior. Kymographs illustrating examples of ASGFP transport behavior. (A) One particle is clearly
seen to bifurcate into two distinct particles (bold arrow). (B) Three starting particles briefly fuse to become one particle (bold arrow) before
bifurcating again into two particles. (C) One particle (bold arrow) moves bidirectionally in and out of a stationary accumulation of ASGFP (fine
arrow) (D) One particle moves without stopping or changing direction (bold arrow) (E) One particle gradually emerges from the background
(bold arrow). (vertical scale bar = 50 μm, horizontal scale bar = 30s).
Table 1 Mean velocities of ASGFP and mutants.
protein variant mean velocity
(μm/sec) ± SEM
p value
ASGFP 1.85 ± .09
A53TGFP 1.56 ± .08 0.0033 *
A30PGFP 1.80 ± .11 0.3409
Δ2GFP 1.71 ± .08 0.0111
Δ3GFP 1.79 ± .09 0.8218
Δ4GFP 1.84 ± .08 0.3064
Δ5GFP 1.68 ± .10 0.1065
Δ6GFP 1.83 ± .18 0.6275
†ASGFP 2.11 ± .09
†Δ234GFP 1.93 ± .14 0.0922
Data were normalized by log transformation, and a pairwise t-test was
performed with Bonferroni correction for multiple comparisons. †Δ234GFP was
compared to ASGFP in an independent experiment, and p values were
determined within experiment.
*significantly different from ASGFP.
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N-terminal helical domain in axonal transport, we
recently reported a number of conformation-dependent
protein binding partners of a-syn, including the micro-
tubule motors kinesin light chain 1S (KLC1S) and
dynein heavy chain I (DHC1) [14]. These partner pro-
teins were identified in a phage display screen using
vesicle-bound a-syn as “bait”. Since vesicle binding
induces a conformational change in the N-terminal
domain encoded by exons 2-4, these conformation-
dependent interactions are likely mediated by the N-ter-
minus, as was confirmed through a detailed structural
characterization of the interaction between a-syn and
endosulfine-alpha [14,44]. Our observation of a lipid-
dependent interaction between a-syn and KLC1S might
account for the inability of Utton et al. [28] to detect a
direct interaction between purified a-syn and kinesin,
Figure 7 Velocity distribution for ASGFP and mutants. Velocities during periods of movement were calculated from kymographs, and mean
± SEM plotted as a percentage of ASGFP velocity. A53TGFP velocity was decreased relative to ASGFP (*p = 0.0033, pairwise t-test with
Bonferroni correction; n>50 movies per group).
* *
Figure 8 Quantitation of motile particles. Primary hippocampal neurons were transfected at 7 DIV. Kymographs were obtained from the
proximal axon segment at 10-14 DIV, and particles displaying >10 μm continuous movement were counted and normalized to the length of
the axon segment. (*p < 0.02 for the comparison with ASGFP, one-way ANOVA with post-hoc Tukey test, n ≥ 9 cells per group)
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despite abundant evidence for anterograde transport of
a-syn. Recently Roy et al. have reported co-transport of
a-syn, synapsin 1, and GAPDH in SCb, and have pro-
posed that these proteins, and perhaps others, could
form a multiprotein complex [42]. We also identified
synapsin 1a as a conformation-dependent binding part-
ner of a-syn [14]. It is thus intriguing to speculate that
a-syn might function as a scaffold mediating microtu-
bule-dependent axonal transport of a macromolecular
complex containing lipid (vesicular membranes or other
lipid-containing particles) and specific proteins.
Conclusions
Presynaptic localization of eGFP-tagged a-syn and
mutant constructs correlated well with previous mea-
surements of lipid affinity and a-helix content. Deletion
of residues encoded by exons 2, 3, or 4 decreased the
relative enrichment of a-syn at presynaptic sites at 17-21
DIV, as did the A30P substitution. Presynaptic enrich-
ment was not correlated with transport velocity, as only
A53T, which binds lipid with a similar affinity as wild-
type protein, showed a significant deficit in axonal trans-
port velocity. However, variations in presynaptic enrich-
ment could relate to other aspects of axonal transport,
including propensity to associate with transport particles,
or retention at specific sites following transport.
Methods
Cell culture and transfection
E18 rat hippocampi (BrainBits Inc., Springfield, IL) were
dispersed and seeded at 1.6 × 104 cells per cm2 onto
poly-D-lysine coated glass coverslip culture plates (Mat-
Tek, Ashland, MA). Cultures were grown in Neuroba-
sal/B27 (Invitrogen, Carlsbad, CA) supplemented with
0.5 mM glutamine and 25 μM glutamate at 37°C, 5%
CO2. Half the volume of medium (without glutamate)
was replaced every 3-4 days.
Neurons were transfected at 7 DIV using Lipofecta-
mine 2000 (Invitrogen). Transfection was carried out
using 1 μg DNA plus 0.5 μl Lipofectamine 2000 per
well as per manufacturer instructions. Neurons were
incubated with the transfection mixture for 10 minutes,
and then switched immediately to Neurobasal/B27 for
one hour. The cells were washed three times with PBS
and subsequently cultured in fresh medium. Transfec-
tion efficiencies of 1-3% were routinely obtained for all
constructs.
All GFP-tagged and mutant constructs of a-syn were
previously generated by Dr. Richard Perrin using a
pEGFP-N3 vector from Clontech (Mountain View, CA).
Immunofluorescence
Neurons were fixed at 17-21 DIV using 4% paraformal-
dehyde for 20 minutes. After washing three times with
PBS, the cells were then permeabilized for 15 minutes
using 0.25% Triton X-100 (Sigma-Aldrich, St. Louis,
MO). Following three more washes with PBS, the sam-
ples were blocked in 10% BSA for 1 hour at 37°C, incu-
bated with primary antibodies (Mouse anti-Synuclein
(H3c), our own lab; Chicken anti-MAP2, Covance; Rab-
bit anti-Synapsin I, Zymed) in 2% BSA for 1 hour at 37°
C, washed three more times in PBS, then incubated
with fluorescently labeled secondary antibody (Alexa
Fluor 488 goat anti-mouse, Alexa Fluor 546 goat anti-
rabbit and Alexa Fluor 633 goat anti-chicken, Invitro-
gen) as before. After three more washes with PBS the
samples were mounted onto microscope slides (Fisher)
using 2% PVA-DABCO (Sigma-Aldrich) and dried over-
night at room temperature. The cells were then visua-
lized on a Leica DM IRE2 fluorescence microscope
(Leica Microsystems, Bannockburn, IL). Images were
acquired using OpenLab Software (Improvision Inc.,
Lexington, MA). For quantification of localization, all
images were acquired at 40× magnification. 15 images
were taken for each a-syn variant. Within each image,
there were multiple processes and each was traced using
the Neuro J program of ImageJ to identify regions of
interest (ROI) of at least 100 μm per sample. ROIs were
finally exported as numerical profiles representing the
pixel intensity measured along that axonal stretch. The
readouts were then used to generate average pixel inten-
sity for the synapse versus axon. Statistic analysis was
done by pairwise t-test with Bonferroni correction using
SAS software.
Live cell imaging
Live fluorescence microscopy was performed on neurons
at 10 DIV. Cells were first rinsed with Hibernate E
(BrainBits, Springfield, IL) as Hibernate E allows mainte-
nance of neurons in ambient carbon dioxide. Hibernate
E containing 2% B27 and 2 mM glutamine was subse-
quently added and used for the remaining imaging per-
iod. Imaging was conducted within a Leica ML
incubator housing a Leica DM IRE2 fluorescent inverted
microscope. Cells were maintained at 37°C using a
Tempcontrol 37-2 digital controller (Pecon GmbH, Ger-
many). Images were acquired at 40× magnification via
OpenLab software and binned (2 × 2) with an exposure
time of 400 ms.
Kymograph analysis
OpenLab was used for acquiring images at a resolution
of 768 × 1024 pixels. Movie segments of 100 frames (~3
minutes imaging time) containing ~100 μm of axonal
processes with moving particles were extracted from the
original images. Maximum Z-projection through the
time series was applied for clearer identification of ROI
using the Neuron J module of ImageJ (NIH). After ROIs
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were identified, kymographs were generated using the
ImageJ plugin “Multiple Kymograph” [45] to facilitate
representation of moving structures in two dimensions.
Intensity values along the ROI are calculated and plotted
with respect to time and position along the ROI. On the
x-axis, each pixel represents ~1.7s, while on the y-axis,
each pixel represents ~0.526 μm. Moving structures
meeting predefined intensity and contrast criteria appear
as contrast edges, the slope of which can be used to
extrapolate velocity. For velocity measurements, only
objects with continuous net movements of at least 10
μm were analyzed and only during periods of motion.
Statistical comparisons of the velocity distributions were
performed using SAS software. The data were first nor-
malized by log transformation, and then a pairwise t-
test was performed with Bonferroni correction for
repeated measures.
Additional file 1: Bidirectional movement of ASGFP particles.
Cultured rat hippocampal neurons were transfected with ASGFP at 7DIV,
with live images acquired at 10 DIV. Arrows (appearing at 32s and 40s,
respectively) indicate distinct particles traveling in opposite directions.
The time stamp at the top right is shown in min:sec:ms and scale bar =
100 μm. The image series is acquired at 1.7s/frame and played back at
0.2s/frame.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1750-1326-5-9-
S1.MOV ]
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